Experts in the News: Campisi, Kirkland, and Musi in MIT Technology Review on early senolytics trial in humans
On February 13, 2019, MIT Technology Review featured insights from AFAR experts Judy Campisi, PhD, James L. Kirkland, MD, PhD, and Nicholas Musi, MD on the first human test of senolytic drugs that could help decrease the impact of age-related diseases.
Dr. Campisi is a 1990 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient.
Dr. Kirkland is AFAR’s Board President-Elect and a 2012 Glenn/AFAR Breakthroughs in Gerontology (BIG) Award recipient.
Dr. Musi is 2007 Beeson Scholar and has served on AFAR’s National Scientific Advisory Council. Additionally, Dr. Musi is co-leader of the Healthspan and Functional Assessment Core at the Nathan Shock Center at UT Health San Antonio, one of the NIA’s six Nathan Shock Centers of Excellence in the Basic Biology of Aging, for which AFAR serves as the Coordinating Center.
Read “A cell-killing strategy to slow aging passed its first test this year” here.